FDA reviewing Churchill's Yonsa for CRPC

Churchill Pharmaceuticals LLC (King of Prussia, Pa.) said FDA accepted for review an NDA for Yonsa abiraterone acetate to treat metastatic castration-resistant prostate cancer (CRPC). Its PDUFA date is March 19, 2018...